Payment overview · 2025
General Payments
$123.70
7 reported records · 3 companies
Healthcare provider profile · identity verified
Thaw Poon, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BALTIMORE, MD · NPI 1912944349
Verified facts
What the public records show
CMS Open Payments records show Thaw Poon, M.D. received $123.70 in general payments during 2025 across 7 reported records.
Novo Nordisk Inc accounted for 45.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Qulipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.68 | 45.8% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $43.95 | 35.5% | 2 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $23.07 | 18.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $123.70 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $56.68 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $56.68 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $43.95 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $43.95 | 2 | 2025 |
Source payment records
|
|||||
| OPZELURA Normalized: opzelura |
Drug | Incyte Corporation | $23.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 175 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
61 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
175 | 40 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 567 | 163 |
| Atorvastatin Calcium | Atorvastatin Calcium | 517 | 148 |
| Losartan Potassium | Losartan Potassium | 378 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 362 | 106 |
| Oxycodone Hcl | Oxycodone Hcl | 349 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 334 | 104 |
| Metoprolol Succinate | Metoprolol Succinate | 304 | 95 |
| Lisinopril | Lisinopril | 295 | 85 |
| Gabapentin | Gabapentin | 274 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 273 | 85 |
| Omeprazole | Omeprazole | 242 | 70 |
| Metformin Hcl | Metformin Hcl | 238 | 71 |
| Eliquis | Apixaban | 227 | 43 |
| Furosemide | Furosemide | 198 | 56 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 198 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 194 | 54 |
| Simvastatin | Simvastatin | 191 | 53 |
| Ozempic | Semaglutide | 175 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 173 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 173 | 52 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 161 | 161 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 161 | 64 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 158 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 158 | 46 |
| Glimepiride | Glimepiride | 137 | 39 |
| Trazodone Hcl | Trazodone Hcl | 136 | 38 |
| Allopurinol | Allopurinol | 128 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 126 | 23 |
| Alprazolam | Alprazolam | 122 | 27 |
| Prednisone | Prednisone | 120 | 79 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 116 | 13 |
| Januvia | Sitagliptin Phosphate | 115 | 25 |
| Montelukast Sodium | Montelukast Sodium | 113 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 110 | 30 |
| Topiramate | Topiramate | 105 | 30 |
| Azithromycin | Azithromycin | 104 | 84 |
| Potassium Chloride | Potassium Chloride | 102 | 34 |
| Famotidine | Famotidine | 101 | 33 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 94 | 68 |
| Doxycycline Hyclate | Doxycycline Hyclate | 92 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 26 |
| Ibuprofen | Ibuprofen | 86 | 29 |
| Sertraline Hcl | Sertraline Hcl | 82 | 27 |
| Lovastatin | Lovastatin | 78 | 24 |
| Pregabalin | Pregabalin | 76 | 18 |
| Xarelto | Rivaroxaban | 75 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 67 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 66 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 26 |
| Linzess | Linaclotide | 61 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 61 | 43 |
| Atenolol | Atenolol | 60 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 17 |
| Tramadol Hcl | Tramadol Hcl | 60 | 15 |
| Alendronate Sodium | Alendronate Sodium | 59 | 15 |
| Carvedilol | Carvedilol | 59 | 20 |
| Nifedipine Er | Nifedipine | 59 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 12 |
| Amoxicillin | Amoxicillin | 57 | 38 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | 14 |
| Meloxicam | Meloxicam | 54 | 20 |
| Cefuroxime | Cefuroxime Axetil | 53 | 41 |
| Mirtazapine | Mirtazapine | 53 | 17 |
| Buspirone Hcl | Buspirone Hcl | 52 | 13 |
| Clonazepam | Clonazepam | 51 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 15 |
| Baclofen | Baclofen | 47 | 11 |
| Jardiance | Empagliflozin | 46 | 11 |
| Synthroid | Levothyroxine Sodium | 45 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Trulicity | Dulaglutide | 43 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 42 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 33 |
| Ventolin Hfa | Albuterol Sulfate | 42 | suppressed |
| Lorazepam | Lorazepam | 41 | suppressed |
| Naproxen | Naproxen | 41 | 11 |
| Metformin Hcl Er | Metformin Hcl | 40 | 12 |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Entresto | Sacubitril/Valsartan | 38 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 12 |
| Ramipril | Ramipril | 35 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 34 | suppressed |
| Lidocaine | Lidocaine | 34 | 13 |
| Spironolactone | Spironolactone | 34 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 31 | 18 |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Oxycontin | Oxycodone Hcl | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Clonidine | Clonidine | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Gemtesa | Vibegron | 29 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Metolazone | Metolazone | 29 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 19 |
| Valsartan | Valsartan | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 21 |
| Nystatin | Nystatin | 25 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Ezetimibe | Ezetimibe | 24 | 11 |
| Irbesartan | Irbesartan | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | 12 |
| Celecoxib | Celecoxib | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 20 | 11 |
| Telmisartan | Telmisartan | 20 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Carbamazepine Er | Carbamazepine | 19 | suppressed |
| Ethacrynic Acid | Ethacrynic Acid | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 13 |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 17 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Nyamyc | Nystatin | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | 11 |
| Methimazole | Methimazole | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Azelaic Acid | Azelaic Acid | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Qulipta | Atogepant | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Orencia | Abatacept | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $123.70 · 7 records | Novo Nordisk Inc | OPZELURA, Ozempic, QULIPTA, Rybelsus, UBRELVY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error